DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main Raises Stake in Dr. Reddy's Laboratories Limited (NYSE:RDY)

DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its stake in Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 400.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 400,000 shares of the company's stock after acquiring an additional 320,000 shares during the quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main's holdings in Dr. Reddy's Laboratories were worth $6,316,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently made changes to their positions in the stock. Robeco Institutional Asset Management B.V. grew its position in Dr. Reddy's Laboratories by 453.8% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company's stock worth $180,620,000 after purchasing an additional 9,373,412 shares during the period. Renaissance Technologies LLC grew its holdings in shares of Dr. Reddy's Laboratories by 382.9% in the fourth quarter. Renaissance Technologies LLC now owns 9,418,428 shares of the company's stock worth $148,717,000 after acquiring an additional 7,467,979 shares during the period. Aikya Investment Management Ltd grew its holdings in shares of Dr. Reddy's Laboratories by 416.1% in the fourth quarter. Aikya Investment Management Ltd now owns 5,610,503 shares of the company's stock worth $88,590,000 after acquiring an additional 4,523,303 shares during the period. Dimensional Fund Advisors LP increased its position in Dr. Reddy's Laboratories by 405.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 5,361,013 shares of the company's stock valued at $84,643,000 after acquiring an additional 4,301,212 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in Dr. Reddy's Laboratories by 397.2% in the fourth quarter. Vanguard Group Inc. now owns 4,896,185 shares of the company's stock valued at $77,311,000 after acquiring an additional 3,911,404 shares during the period. 3.85% of the stock is owned by hedge funds and other institutional investors.

Dr. Reddy's Laboratories Stock Performance

NYSE RDY traded up $0.53 during trading hours on Monday, hitting $13.93. 2,353,877 shares of the company's stock traded hands, compared to its average volume of 1,490,595. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02. Dr. Reddy's Laboratories Limited has a 52 week low of $12.26 and a 52 week high of $16.89. The firm has a market capitalization of $11.62 billion, a P/E ratio of 22.17 and a beta of 0.33. The business's fifty day moving average price is $13.31 and its two-hundred day moving average price is $14.05.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last posted its quarterly earnings data on Friday, May 9th. The company reported $0.22 EPS for the quarter, topping the consensus estimate of $0.20 by $0.02. The firm had revenue of $996.17 million during the quarter, compared to analyst estimates of $83.70 billion. Dr. Reddy's Laboratories had a return on equity of 17.87% and a net margin of 17.25%. Equities research analysts predict that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current year.

Analysts Set New Price Targets

Separately, StockNews.com raised Dr. Reddy's Laboratories from a "hold" rating to a "buy" rating in a research report on Thursday.

Dr. Reddy's Laboratories Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.